• +1-646-491-9876
    • +91-20-67278686

    Search

    Radiodermatitis-Pipeline Review H1 2017

    Radiodermatitis-Pipeline Review H1 2017

    • Report Code ID: RW0001834412
    • Category Pharmaceuticals
    • No. of Pages 41
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Radiodermatitis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Radiodermatitis - Pipeline Review, H1 2017, provides an overview of the Radiodermatitis (Toxicology) pipeline landscape.

    Radiodermatitis is an inflammation of the skin caused by radiation. Several factors can be attributed to the varying response of patients' skin to radiation therapy such as treatment-related factors such as individual fraction size, type of energy, and the use of bolus doses can impact skin reactions. Host factors also may play a role in the development of radiodermatitis; they include genetic factors, personal factors, existing skin integrity issues, comorbid conditions, nutritional status, age, race and ethnicity, medications, sun exposure, smoking, and mobility.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Radiodermatitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Radiodermatitis (Toxicology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Radiodermatitis (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Radiodermatitis (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Radiodermatitis (Toxicology) .
    - The pipeline guide reviews pipeline therapeutics for Radiodermatitis (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Radiodermatitis (Toxicology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Radiodermatitis (Toxicology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Radiodermatitis (Toxicology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Radiodermatitis (Toxicology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Radiodermatitis (Toxicology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Radiodermatitis - Overview
    Radiodermatitis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Radiodermatitis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Radiodermatitis - Companies Involved in Therapeutics Development
    Daiichi Sankyo Company Ltd
    FirstString Research Inc
    Foresee Pharmaceuticals LLC
    Reata Pharmaceuticals Inc
    SK Chemicals Co Ltd
    viDA Therapeutics Inc
    Radiodermatitis - Drug Profiles
    cerium oxide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FP-045 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Granexin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    omaveloxolone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    phenylbutyrate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RS-9 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SKI-2162 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize Adenosine A2A Receptor for Radiation Dermatitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VTI-1000 Series - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Radiodermatitis - Dormant Projects
    Radiodermatitis - Discontinued Products
    Radiodermatitis - Product Development Milestones
    Featured News & Press Releases
    Jul 25, 2014: Reata Enrolls First Patient in the PRIMROSE Study, a Phase 2 Study Examining RTA 408 in Breast Cancer Patients at Risk for Radiation Dermatitis
    Apr 24, 2014: RTA 408 Lotion Demonstrates Favorable Safety and Pharmacodynamic Response in a Phase 1 Study
    Apr 10, 2014: Preclinical Study of Reata's RTA 408 Demonstrates Role in Prevention and Treatment of Radiation Dermatitis
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Radiodermatitis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Radiodermatitis - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Radiodermatitis - Pipeline by FirstString Research Inc, H1 2017
    Radiodermatitis - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
    Radiodermatitis - Pipeline by Reata Pharmaceuticals Inc, H1 2017
    Radiodermatitis - Pipeline by SK Chemicals Co Ltd, H1 2017
    Radiodermatitis - Pipeline by viDA Therapeutics Inc, H1 2017
    Radiodermatitis - Dormant Projects, H1 2017
    Radiodermatitis - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Radiodermatitis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Daiichi Sankyo Company Ltd
    FirstString Research Inc
    Foresee Pharmaceuticals LLC
    Reata Pharmaceuticals Inc
    SK Chemicals Co Ltd
    viDA Therapeutics Inc

    Request for Sample

    Report Url http://www.reportsweb.com//radiodermatitis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//radiodermatitis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//radiodermatitis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments